Merck lifts sales forecast as newer drugs gain momentum (MRK:NYSE)
· seekingalpha.com
Merck Q2 earnings beat estimates on Keytruda and Winrevair sales; revenue rose 5% and guidance was raised.
Merck (MRK) reported second-quarter results that topped Wall Street expectations, driven by continued strength in its blockbuster cancer drug Keytruda, as well ...